AGENUS INC Other Non-Current Liabilities
AGENUS INC (AGEN) had Other Non-Current Liabilities of $247.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2026-08-07
- 2026-06-30: Other Liabilities, Noncurrent $247.00K.
- 2026-03-31: Other Liabilities, Noncurrent $247.00K.
- 2025-12-31: Other Liabilities, Noncurrent $259.00K.
- 2025-09-30: Other Liabilities, Noncurrent $376.00K.
| Period end | Other Liabilities, Noncurrent | Other Liabilities, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $247.00K 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $247.00K 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $259.00K 10-Q · filed 2026-08-07 | |
| 2025-09-30 | $376.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $752.00K 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $761.00K 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $738.00K 10-K · filed 2026-03-16 | |
| 2024-09-30 | $777.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $1.49M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $2.73M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $5.42M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $8.31M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $11.07M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $13.91M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $14.70M 10-K · filed 2024-03-14 | $13.83M 10-K · filed 2023-03-16 |
| 2022-09-30 | $1.47M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $1.80M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $1.43M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $1.58M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $1.89M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $1.75M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $1.64M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $1.51M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $6.86M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $6.42M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $6.50M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $4.19M 10-K · filed 2021-03-16 | |
| 2019-09-30 | $4.09M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $3.10M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $798.00K 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $2.77M 10-K · filed 2020-03-16 | $2.77M 10-K · filed 2019-03-18 |
| 2018-09-30 | $2.91M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $3.08M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $3.15M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $3.27M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $4.76M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $4.84M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $4.80M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $4.81M 10-K · filed 2018-03-16 | |
| 2016-09-30 | $4.81M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $4.77M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $7.80M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $7.57M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $7.55M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $7.56M 10-Q · filed 2015-08-03 | |
| 2015-03-31 | $2.99M 10-Q · filed 2015-05-01 | |
| 2014-12-31 | $2.80M 10-K · filed 2016-03-15 | |
| 2014-09-30 | $2.63M 10-Q · filed 2014-10-31 | |
| 2014-06-30 | $2.67M 10-Q · filed 2014-08-01 | |
| 2014-03-31 | $2.65M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $1.68M 10-K · filed 2015-03-16 | |
| 2013-09-30 | $1.65M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $1.62M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $1.47M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $1.37M 10-K · filed 2014-03-07 | |
| 2012-09-30 | $1.29M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $945.21K 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $1.03M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $1.08M 10-K · filed 2013-03-18 | |
| 2011-09-30 | $1.19M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $1.28M 10-Q · filed 2011-08-05 | |
| 2010-12-31 | $1.78M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |